Variable | Total(n = 117) | Mono-CA-BSI(n = 93) | Mixed-CA/B-BSIs(n = 24) | P value |
---|---|---|---|---|
Source of candidaemia [n (%)] | ||||
  Definitive CVC-related | 34 (29.1%) | 27 (29.0%) | 7 (29.2%) | 0.990 |
 Intra-abdominal | 24 (20.5%) | 18 (19.4%) | 6 (25.0%) | 0.744 |
  Primary | 22 (18.8%) | 15 (16.1%) | 7 (29.2%) | 0.244 |
  Lower respiratory tract | 12 (10.3%) | 11 (11.8%) | 1 (4.2%) | 0.468 |
 Urinary tract infection | 7 (6.0%) | 6 (6.5%) | 1 (4.2%) | > 0.999 |
 Gastrointestinal tract | 6 (5.1%) | 6 (6.5%) | 0 (0.0%) | 0.344 |
 Skin and Soft tissue | 5 (4.3%) | 4 (4.3%) | 1 (4.2%) | > 0.999 |
 Meningitis | 3 (2.6%) | 2 (2.2%) | 1 (4.2%) | 0.501 |
 Endocardium | 2 (1.7%) | 2 (2.2%) | 0 (0.0%) | > 0.999 |
 Osteoarthritis | 1 (0.9%) | 1 (1.1%) | 0 (0.0%) | > 0.999 |
Source control [n (%)] | ||||
 Removal of contaminated lines a | 40 (34.2%) | 27 (29.0%) | 13 (54.2%) | 0.021 |
 Draining of fungal collection | 19 (16.2%) | 14 (15.1%) | 5 (20.8%) | 0.708 |
Days of prior antibiotic exposure (IQR) | 11.0 (3.0,22.0) | 8.0 (1.0,20.5) | 17.0 (10.3,28.8) | 0.007 |
Prior antibiotic exposure b [n (%)] | 93 (79.5%) | 69 (74.2%) | 24 (100.0%) | 0.012 |
 Cephalosporins | 33 (28.2%) | 25 (26.9%) | 8 (33.3%) | 0.531 |
 Carbapenems | 49 (41.9%) | 41 (44.1%) | 8 (33.3%) | 0.341 |
 Penicillins | 25 (21.4%) | 19 (20.4%) | 6 (25.0%) | 0.626 |
 Quinolones | 4 (3.4%) | 4 (4.3%) | 0 (0.0%) | 0.580 |
Initial antifungal agent [n (%)] | ||||
 Fluconazole | 40 (34.2%) | 32 (34.4%) | 8 (33.3%) | 0.921 |
 Echinocandin | 46 (39.3%) | 36 (38.7%) | 10 (41.7%) | 0.791 |
 Voriconazole | 11 (9.4%) | 9 (9.7%) | 2 (8.3%) | > 0.999 |
Prior antifungal exposure [n (%)] | 10 (8.5%) | 6 (6.4%) | 4 (16.7%) | 0.235 |
Appropriate Antifungal therapy c [n (%)] | 43 (36.8%) | 35 (37.6%) | 8 (33.3%) | 0.697 |
Delay in initiation of empiric antifungal treatment d [n (%)] | 100 (85.5%) | 82 (88.2%) | 18 (75.0%) | 0.103 |